Nifty
:
14581.45
Sensex
:
48803.68
76.65 (0.53%)
259.62 (0.53%)
Nifty
Sensex
:
:
14581.45
48803.68
76.65 (0.53%)
259.62 (0.53%)

Aurobindo Pharma Ltd.

Pharmaceuticals & Drugs - Global

Rating :
67/99

BSE: 524804 | NSE: AUROPHARMA

NSE BSE
915.25
15-Apr-2021
  • Open
  • High
  • Low
  • Previous Close
  •  917.00
  •  932.00
  •  900.00
  •  909.25
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  4393581
  •  40308.17
  •  1023.70
  •  511.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 53,592.87
  • 9.90
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 56,312.69
  • 0.33%
  • 2.50

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.94%
  • 0.98%
  • 8.78%
  • FII
  • DII
  • Others
  • 24.99%
  • 12.58%
  • 0.73%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.09
  • 10.86
  • 11.95

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.58
  • 8.82
  • 5.22

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.58
  • 7.06
  • 5.55

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.23
  • 16.65
  • 15.53

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.23
  • 3.51
  • 2.75

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 11.89
  • 11.08
  • 10.11

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Net Sales
6,364.91
5,895.00
7.97%
6,483.44
5,600.47
15.77%
5,924.78
5,444.60
8.82%
6,158.43
5,292.20
16.37%
Expenses
4,996.33
4,686.96
6.60%
5,050.63
4,460.25
13.24%
4,667.43
4,298.20
8.59%
4,842.21
4,234.73
14.35%
EBITDA
1,368.58
1,208.04
13.29%
1,432.81
1,140.22
25.66%
1,257.35
1,146.40
9.68%
1,316.22
1,057.47
24.47%
EBIDTM
21.50%
20.49%
22.10%
20.36%
21.22%
21.06%
21.37%
19.98%
Other Income
133.40
30.93
331.30%
53.75
20.62
160.67%
115.59
15.78
632.51%
32.59
32.27
0.99%
Interest
19.49
37.11
-47.48%
15.71
40.94
-61.63%
21.07
49.89
-57.77%
31.83
50.08
-36.44%
Depreciation
276.52
250.13
10.55%
257.34
243.31
5.77%
255.52
240.86
6.09%
232.41
186.62
24.54%
PBT
4,019.86
938.81
328.19%
1,213.51
863.83
40.48%
1,096.35
858.73
27.67%
1,096.82
816.86
34.27%
Tax
1,059.08
232.86
354.81%
387.33
224.37
72.63%
303.67
227.76
33.33%
228.52
231.12
-1.12%
PAT
2,960.78
705.95
319.40%
826.18
639.46
29.20%
792.68
630.97
25.63%
868.30
585.74
48.24%
PATM
46.52%
11.98%
12.74%
11.42%
13.38%
11.59%
14.10%
11.07%
EPS
50.29
12.04
317.69%
13.76
10.92
26.01%
13.32
10.85
22.76%
14.50
9.99
45.15%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
24,931.56
23,098.51
19,563.55
16,463.03
14,909.54
13,794.65
12,120.52
8,099.79
5,855.32
4,627.40
4,381.48
Net Sales Growth
12.14%
18.07%
18.83%
10.42%
8.08%
13.81%
49.64%
38.33%
26.54%
5.61%
 
Cost Of Goods Sold
9,998.76
8,720.74
7,886.32
6,085.55
5,911.00
5,612.30
5,099.89
3,275.54
2,730.00
2,303.99
1,963.83
Gross Profit
14,932.80
14,377.77
11,677.23
10,377.48
8,998.54
8,182.35
7,020.63
4,824.25
3,125.32
2,323.41
2,417.65
GP Margin
59.90%
62.25%
59.69%
63.04%
60.35%
59.32%
57.92%
59.56%
53.38%
50.21%
55.18%
Total Expenditure
19,556.60
18,234.20
15,611.61
12,691.28
11,475.26
10,606.53
9,556.90
5,966.14
4,994.37
4,066.10
3,418.22
Power & Fuel Cost
-
587.68
556.79
470.95
437.14
419.26
359.60
349.84
324.72
232.36
208.26
% Of Sales
-
2.54%
2.85%
2.86%
2.93%
3.04%
2.97%
4.32%
5.55%
5.02%
4.75%
Employee Cost
-
3,219.18
2,584.87
2,130.84
1,767.76
1,542.62
1,302.26
802.43
663.31
535.69
425.07
% Of Sales
-
13.94%
13.21%
12.94%
11.86%
11.18%
10.74%
9.91%
11.33%
11.58%
9.70%
Manufacturing Exp.
-
2,331.41
2,037.95
1,611.12
1,309.64
1,256.18
1,022.70
772.04
623.04
543.16
511.60
% Of Sales
-
10.09%
10.42%
9.79%
8.78%
9.11%
8.44%
9.53%
10.64%
11.74%
11.68%
General & Admin Exp.
-
1,320.69
1,006.68
1,068.22
997.32
686.38
666.38
283.49
197.83
130.74
120.34
% Of Sales
-
5.72%
5.15%
6.49%
6.69%
4.98%
5.50%
3.50%
3.38%
2.83%
2.75%
Selling & Distn. Exp.
-
1,524.75
1,125.76
1,025.85
848.43
901.87
878.98
359.60
305.98
208.20
141.59
% Of Sales
-
6.60%
5.75%
6.23%
5.69%
6.54%
7.25%
4.44%
5.23%
4.50%
3.23%
Miscellaneous Exp.
-
529.75
413.24
298.75
203.97
187.92
227.09
123.20
149.49
111.96
141.59
% Of Sales
-
2.29%
2.11%
1.81%
1.37%
1.36%
1.87%
1.52%
2.55%
2.42%
1.08%
EBITDA
5,374.96
4,864.31
3,951.94
3,771.75
3,434.28
3,188.12
2,563.62
2,133.65
860.95
561.30
963.26
EBITDA Margin
21.56%
21.06%
20.20%
22.91%
23.03%
23.11%
21.15%
26.34%
14.70%
12.13%
21.98%
Other Income
335.33
191.87
155.32
101.98
115.89
203.80
96.71
21.56
28.54
24.70
71.41
Interest
88.10
305.13
262.60
77.72
66.72
256.70
159.87
310.16
266.64
277.24
64.65
Depreciation
1,021.79
966.71
667.95
557.97
427.63
392.37
332.61
312.53
248.74
200.53
171.50
PBT
7,426.54
3,784.34
3,176.71
3,238.04
3,055.82
2,742.85
2,167.85
1,532.52
374.11
108.23
798.52
Tax
1,978.60
913.52
726.85
818.27
759.65
720.71
596.59
363.45
82.71
-88.81
225.12
Tax Rate
26.64%
24.31%
23.53%
25.27%
24.86%
26.28%
27.52%
23.72%
22.11%
41.70%
28.56%
PAT
5,447.94
2,846.14
2,362.03
2,420.03
2,296.64
2,023.64
1,575.77
1,172.85
293.86
-123.50
563.45
PAT before Minority Interest
5,449.40
2,844.69
2,361.80
2,419.77
2,296.17
2,022.14
1,571.26
1,169.07
291.40
-124.14
563.06
Minority Interest
1.46
1.45
0.23
0.26
0.47
1.50
4.51
3.78
2.46
0.64
0.39
PAT Margin
21.85%
12.32%
12.07%
14.70%
15.40%
14.67%
13.00%
14.48%
5.02%
-2.67%
12.86%
PAT Growth
112.63%
20.50%
-2.40%
5.37%
13.49%
28.42%
34.35%
299.12%
-
-
 
EPS
92.98
48.58
40.31
41.30
39.20
34.54
26.89
20.02
5.02
-2.11
9.62

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
16,810.38
13,890.78
11,680.42
9,371.91
7,287.30
5,155.91
3,750.15
2,605.76
2,339.65
2,444.83
Share Capital
58.59
58.59
58.59
58.59
58.52
29.20
29.15
29.12
29.11
29.11
Total Reserves
16,751.79
13,832.13
11,621.76
9,313.22
7,227.50
5,126.71
3,721.00
2,576.64
2,310.54
2,415.72
Non-Current Liabilities
565.88
358.13
594.11
102.07
583.85
1,591.60
1,493.91
1,225.26
967.29
645.49
Secured Loans
0.00
48.88
451.20
177.59
380.10
773.54
1,101.31
1,084.11
862.08
449.74
Unsecured Loans
0.00
131.07
0.00
3.81
362.71
587.93
178.05
64.15
102.55
73.61
Long Term Provisions
74.71
46.54
55.86
39.13
23.36
24.35
9.18
9.00
4.24
3.09
Current Liabilities
11,386.75
12,020.57
8,665.89
6,605.60
7,840.22
6,136.40
4,220.04
3,430.83
2,915.05
2,768.49
Trade Payables
2,545.01
2,552.18
2,372.90
2,154.70
2,457.03
2,051.13
1,351.20
963.75
660.14
776.35
Other Current Liabilities
2,874.56
2,510.51
1,967.42
1,286.82
1,577.58
1,364.95
387.68
150.87
580.34
699.09
Short Term Borrowings
5,422.30
6,573.21
4,031.34
2,902.72
3,672.68
2,502.08
2,354.56
2,236.12
1,608.21
1,234.73
Short Term Provisions
544.88
384.67
294.23
261.36
132.93
218.24
126.60
80.09
66.36
58.32
Total Liabilities
28,763.15
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
6,232.20
5,867.93
Net Block
9,396.47
8,474.85
6,520.68
4,833.78
4,179.69
3,705.64
2,721.67
2,638.87
2,194.65
1,738.60
Gross Block
12,441.26
10,497.62
7,894.78
5,635.49
4,569.83
5,446.13
4,182.96
3,763.47
3,086.25
2,438.00
Accumulated Depreciation
3,044.79
2,022.77
1,374.10
801.71
390.14
1,740.49
1,461.29
1,124.60
891.60
699.40
Non Current Assets
12,350.65
10,938.77
8,764.08
6,875.48
5,419.57
4,610.93
3,858.59
3,136.10
2,968.16
2,546.75
Capital Work in Progress
1,985.94
1,668.46
1,583.04
1,458.08
848.14
370.35
256.67
167.82
515.74
582.86
Non Current Investment
554.69
360.20
311.52
245.85
122.94
0.14
19.76
22.24
19.86
38.49
Long Term Loans & Adv.
376.94
396.64
261.91
256.48
236.56
455.27
789.04
237.82
108.12
110.77
Other Non Current Assets
36.61
38.62
86.93
81.29
32.24
30.25
18.40
18.66
0.12
1.47
Current Assets
16,412.50
15,332.30
12,178.16
9,206.18
10,294.35
8,298.80
5,631.18
4,136.75
3,264.04
3,321.18
Current Investments
0.02
0.02
0.02
0.02
0.02
19.65
0.03
0.04
18.68
0.04
Inventories
7,699.87
7,245.60
5,858.41
4,330.54
4,056.14
3,611.30
2,367.54
1,923.59
1,545.56
1,455.27
Sundry Debtors
4,315.15
3,413.78
3,080.20
2,765.33
4,606.68
3,539.17
2,636.57
1,596.98
1,239.96
1,230.98
Cash & Bank
2,842.15
1,957.18
1,262.25
513.48
800.26
469.11
178.58
208.45
70.86
186.72
Other Current Assets
1,555.31
1,919.82
1,223.32
1,084.72
831.25
659.57
448.46
407.69
388.98
448.17
Short Term Loans & Adv.
1,065.96
795.90
753.96
512.09
366.88
387.90
237.22
207.51
216.67
358.87
Net Current Assets
5,025.75
3,311.73
3,512.27
2,600.58
2,454.13
2,162.40
1,411.14
705.92
348.99
552.69
Total Assets
28,763.15
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
6,232.20
5,867.93

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
4,381.28
1,650.97
1,954.52
3,278.58
1,419.76
1,236.81
646.28
274.87
326.25
335.11
PBT
3,743.04
3,091.35
3,241.18
3,060.84
2,744.30
2,167.85
1,532.52
374.11
108.23
798.52
Adjustment
1,091.17
813.95
535.02
408.92
487.50
406.28
515.12
441.54
387.22
197.72
Changes in Working Capital
276.87
-1,484.50
-1,123.12
582.52
-1,079.41
-841.73
-1,057.41
-421.56
-128.34
-469.45
Cash after chg. in Working capital
5,111.08
2,420.80
2,653.08
4,052.28
2,152.39
1,732.40
990.23
394.09
367.11
526.79
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-729.80
-769.83
-698.56
-773.70
-732.63
-495.59
-343.95
-119.22
-40.86
-191.68
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,567.64
-2,902.59
-1,926.59
-1,787.04
-1,445.21
-1,397.97
-818.74
-246.34
-563.16
-599.07
Net Fixed Assets
-606.64
-799.00
-771.00
-1,092.24
125.11
-533.87
-141.02
-224.46
-376.05
-396.28
Net Investments
-180.64
-371.56
-285.55
-498.60
-170.60
-140.13
-164.64
-78.98
-135.92
-122.17
Others
-780.36
-1,732.03
-870.04
-196.20
-1,399.72
-723.97
-513.08
57.10
-51.19
-80.62
Cash from Financing Activity
-1,947.18
1,919.06
864.15
-1,915.26
365.44
93.21
117.64
108.09
118.85
406.98
Net Cash Inflow / Outflow
866.46
667.44
892.08
-423.72
339.99
-67.95
-54.82
136.62
-118.06
143.02
Opening Cash & Equivalents
1,875.58
1,209.94
318.03
743.49
403.81
148.02
202.73
65.64
183.71
44.72
Closing Cash & Equivalent
2,746.82
1,875.58
1,209.94
319.63
743.50
461.10
148.02
202.73
65.64
183.71

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
286.92
237.08
199.36
159.96
124.50
88.29
64.33
44.74
40.19
41.99
ROA
10.34%
10.00%
13.07%
14.44%
14.13%
14.03%
13.95%
4.32%
-2.05%
10.57%
ROE
18.53%
18.47%
22.99%
27.57%
32.51%
35.29%
36.79%
11.78%
-5.19%
26.35%
ROCE
18.80%
17.97%
22.72%
24.92%
27.35%
27.18%
27.18%
11.17%
1.25%
19.29%
Fixed Asset Turnover
4.12
4.36
2.44
2.96
2.79
2.55
2.08
1.75
1.71
1.85
Receivable days
29.85
29.56
64.66
89.16
106.53
91.84
93.55
86.28
95.44
89.07
Inventory Days
57.72
59.64
112.70
101.43
100.27
88.91
94.82
105.51
115.91
104.17
Payable days
52.98
58.56
67.77
75.73
81.50
67.49
71.06
57.79
64.70
70.79
Cash Conversion Cycle
34.59
30.63
109.58
114.86
125.30
113.25
117.31
134.00
146.65
122.45
Total Debt/Equity
0.33
0.50
0.41
0.36
0.69
0.86
1.01
1.32
1.32
0.99
Interest Cover
13.32
12.76
42.66
46.80
11.69
14.56
5.94
2.40
0.23
13.19

Annual Reports:

FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011

News Update:


  • Aurobindo Pharma inks pact to invest in two solar power companies
    24th Feb 2021, 09:09 AM

    The company has invested in the two firms to avail the benefit of captive consumption of solar power

    Read More
  • Aurobindo Pharma gets USFDA’s final nod to manufacture, market Droxidopa Capsules
    19th Feb 2021, 11:47 AM

    The approved product has an estimated market size of $352 million for the twelve months ending December 2020

    Read More
  • Aurobindo Pharma’s unit recalling 3,094 cartons of Acetaminophen injection
    15th Feb 2021, 10:57 AM

    The drug is used to relieve mild to moderate pain and reduce fever

    Read More
  • Aurobindo Pharma gets nod for promotion of manufacturing critical bulk drugs
    23rd Jan 2021, 10:05 AM

    The approval has also been given to Aurobindo Pharma (through Qule Pharma) for setting up plant for production of Erythromycin Thiocyanate

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.